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Letters to the Editor
Progression of HCV infection in patients with chronic kidney disease
To the Editor:
We read with great interest the excellent review by
Martin and Fabrizi [1] recently published in Journal of
Hepatology, regarding the HCV infection in patients
with chronic kidney disease (CKD). Rightly, the authors
emphasized that advanced ﬁbrosis is a common histo-
logic ﬁnding in this group of patients despite ‘normal’
aminotransferase values, making liver biopsy (LB) man-
datory for accurate assessment of the liver damage [1].
The authors also commented on previous published
studies, which found no signiﬁcant diﬀerence in ﬁbrosis
in chronic hepatitis C (CHC) patients with or without
CKD [1].
However, we feel further comment and clariﬁcation
is necessary about this issue, since others have found a
lower incidence of severe ﬁbrosis in CHC patients
with CKD in reports [2–4] not commented on in the
review [1]. For example, Hu et al. [2] compared 91
CHC patients with end-stage renal disease on dialysis
and 159 CHC patients with normal renal function.
Those with renal disease had less detectable hepatic
ﬁbrosis (i.e. from stage 1 to 4 according to modiﬁed
Knodell’s scoring system) and advanced ﬁbrosis (i.e.
stages 3–4), compared to those without renal dysfunc-
tion. These ﬁndings conﬁrm previous studies [3,4], in
which the histological lesions were less severe in
CHC patients with CKD receiving haemodialysis,
compared to those without CKD. In addition, Martin
et al. [5] reported that the severity of histologic dam-
age was less in dialysed patients than pre-dialysis
CKD patients with CHC.
Although there is no clear explanation, there has been
speculation that hemodialysis or uremic serum per se
may lead to viral suppression. Our recent report sup-
ports this hypothesis. We described 2 patients with
recurrent HCV infection after liver transplantation
(LT) in whom the HCV RNA by PCR became perma-
nently negative without antiviral therapy several years
after transplantation [6]. Both patients were under sirol-
imus administration and had developed CKD, one due
to nephrotic syndrome and one due to tacrolimus
nephrotoxicity.
Patients who are transplanted for HCV-related cir-
rhosis nearly all develop recurrent HCV infection
post-LT, which has negative impact on post-LT out-
come. Although several studies have shown that the
course of recurrent HCV is compressed and more
aggressive, the precise factors which aﬀect this course
after LT have not been completely elucidated [7].
Interestingly, in a study we have published in abstract
form [8], we found that the presence of renal dysfunc-
tion in patients with recurrent HCV after LT was
associated with slower progression of ﬁbrosis. In par-
ticular, we evaluated 102 consecutive patients, and in
each, the changes in serum creatinine (DCr), necroin-
ﬂammation (Dgrade) and ﬁbrosis (Dstage) between
consecutive LB, were recorded. We found that the pa-
tients with stable or worse Cr (DCrP 0) between the
1st and 2nd LB, compared to the patients with Cr
improvement (DCr < 0), had less severe yearly progres-
sion in ﬁbrosis (mean Dstage/year: 0.28 vs 0.65,
respectively, p = 0.05) despite similar clinical (e.g.
immunosuppressive therapy) or laboratory (e.g. ami-
notransferases) characteristics. Interestingly, the pa-
tients with CKD, compared to those who
maintained normal creatinine values long-term, had
signiﬁcantly slower ﬁbrosis progression (Dstage/year:
0.11 vs 0.74, p = 0.037).
Based on the ﬁndings in the pre-(2–4) and post-LT
setting [8], we believe that further evaluation is needed
in order to elucidate the exact association between the
severity of HCV and CKD, which may have signiﬁcant
implications for new interventions in these patients.
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Progression of HCV infection in patients with chronic
kidney disease: Reply
To the Editor:
We thank Dr. Cholongitas and colleagues for their
comments on our recent review in this Journal on
HCV in patients with chronic kidney disease (CKD)
and for highlighting ﬁndings from other groups who
have performed liver biopsies in these patients. As they
note we had suggested in a paper several years ago that
hemodialysis or perhaps uremia may provide some pro-
tective eﬀect against ﬁbrosis development in patients
with HCV infection [1]. As cited in our paper, an inter-
national group of hepatologists and nephrologists has
developed guidelines, under the auspices of the National
Kidney Foundation, to guide the management of pa-
tients with CKD and HCV infection [2]. Prospective
studies with serial liver biopsies are clearly required in
this patient population to further deﬁne the natural his-
tory of HCV infection at various stages of CKD includ-
ing post renal transplantation particularly as treatment
options for HCV expand.
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Hepatitis E virus as an emerging cause of chronic liver disease
in organ transplant recipients
To the Editor:
We read with great interest the very complete and up-
to-date review by R.H. Purcell and S.U. Emerson on
hepatitis E virus (HEV) [1]. It highlights that this virus
is the leading or the second leading cause of acute hep-
atitis in adults in many parts of the developing world,
and that an increasing number of sporadic autochtho-
nous acute hepatitis E cases have been recently reported
in industrialized countries [1]. Unexpectedly, a new clin-
ical feature has just been described in association with
autochthonous hepatitis E virus (HEV) infections in
developed countries [2–4]. Indeed, since February
2008, cases of HEV-related chronic hepatitis have been
reported in organ transplant recipients by three diﬀerent
teams, including ours. This ﬁnding still adds signiﬁcant
interest to hepatitis E, and questions the extent and
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